Julie L Engers, Katrina A Bollinger, Rory A Capstick, Madeline F Long, Aaron M Bender, Jonathan W Dickerson, Weimin Peng, Christopher C Presley, Hyekyung P Cho, Alice L Rodriguez, Colleen M Niswender, Sean P Moran, Zixiu Xiang, Anna L Blobaum, Olivier Boutaud, Jerri M Rook, Darren W Engers, P Jeffrey Conn, Craig W Lindsley
{"title":"发现 VU6007496:开发 M1 阳性变构调节剂后备候选药物的挑战。","authors":"Julie L Engers, Katrina A Bollinger, Rory A Capstick, Madeline F Long, Aaron M Bender, Jonathan W Dickerson, Weimin Peng, Christopher C Presley, Hyekyung P Cho, Alice L Rodriguez, Colleen M Niswender, Sean P Moran, Zixiu Xiang, Anna L Blobaum, Olivier Boutaud, Jerri M Rook, Darren W Engers, P Jeffrey Conn, Craig W Lindsley","doi":"10.1021/acschemneuro.4c00508","DOIUrl":null,"url":null,"abstract":"<p><p>Herein we report progress toward a backup clinical candidate to the M<sub>1</sub> positive allosteric modulator (PAM) VU319/ACP-319. Scaffold-hopping from the pyrrolo[2,3-<i>b</i>]pyridine-based M<sub>1</sub> PAM VU6007477 to isomeric pyrrolo[3,2-<i>b</i>]pyridine and thieno[3,2-<i>b</i>]pyridine congeners identified several backup contenders. Ultimately, VU6007496, a pyrrolo[3,2-<i>b</i>]pyridine, advanced into late stage profiling, only to be plagued with unanticipated, species-specific metabolism and active/toxic metabolites which were identified in our phenotypic seizure liability <i>in vivo</i> screen, preventing further development. However, VU6007496 proved to be a highly selective and CNS penetrant M<sub>1</sub> PAM, with minimal agonism, that displayed excellent multispecies IV/PO pharmacokinetics (PK), CNS penetration, no induction of long-term depression (or cholinergic toxicity) and robust efficacy in novel object recognition (minimum effective dose = 3 mg/kg p.o.). Thus, VU6007496 can serve as another valuable <i>in vivo</i> tool compound in rats and nonhuman primates, but not mouse, to study selective M<sub>1</sub> activation.</p>","PeriodicalId":13,"journal":{"name":"ACS Chemical Neuroscience","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413853/pdf/","citationCount":"0","resultStr":"{\"title\":\"Discovery of VU6007496: Challenges in the Development of an M<sub>1</sub> Positive Allosteric Modulator Backup Candidate.\",\"authors\":\"Julie L Engers, Katrina A Bollinger, Rory A Capstick, Madeline F Long, Aaron M Bender, Jonathan W Dickerson, Weimin Peng, Christopher C Presley, Hyekyung P Cho, Alice L Rodriguez, Colleen M Niswender, Sean P Moran, Zixiu Xiang, Anna L Blobaum, Olivier Boutaud, Jerri M Rook, Darren W Engers, P Jeffrey Conn, Craig W Lindsley\",\"doi\":\"10.1021/acschemneuro.4c00508\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Herein we report progress toward a backup clinical candidate to the M<sub>1</sub> positive allosteric modulator (PAM) VU319/ACP-319. Scaffold-hopping from the pyrrolo[2,3-<i>b</i>]pyridine-based M<sub>1</sub> PAM VU6007477 to isomeric pyrrolo[3,2-<i>b</i>]pyridine and thieno[3,2-<i>b</i>]pyridine congeners identified several backup contenders. Ultimately, VU6007496, a pyrrolo[3,2-<i>b</i>]pyridine, advanced into late stage profiling, only to be plagued with unanticipated, species-specific metabolism and active/toxic metabolites which were identified in our phenotypic seizure liability <i>in vivo</i> screen, preventing further development. However, VU6007496 proved to be a highly selective and CNS penetrant M<sub>1</sub> PAM, with minimal agonism, that displayed excellent multispecies IV/PO pharmacokinetics (PK), CNS penetration, no induction of long-term depression (or cholinergic toxicity) and robust efficacy in novel object recognition (minimum effective dose = 3 mg/kg p.o.). Thus, VU6007496 can serve as another valuable <i>in vivo</i> tool compound in rats and nonhuman primates, but not mouse, to study selective M<sub>1</sub> activation.</p>\",\"PeriodicalId\":13,\"journal\":{\"name\":\"ACS Chemical Neuroscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413853/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Chemical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acschemneuro.4c00508\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acschemneuro.4c00508","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup Candidate.
Herein we report progress toward a backup clinical candidate to the M1 positive allosteric modulator (PAM) VU319/ACP-319. Scaffold-hopping from the pyrrolo[2,3-b]pyridine-based M1 PAM VU6007477 to isomeric pyrrolo[3,2-b]pyridine and thieno[3,2-b]pyridine congeners identified several backup contenders. Ultimately, VU6007496, a pyrrolo[3,2-b]pyridine, advanced into late stage profiling, only to be plagued with unanticipated, species-specific metabolism and active/toxic metabolites which were identified in our phenotypic seizure liability in vivo screen, preventing further development. However, VU6007496 proved to be a highly selective and CNS penetrant M1 PAM, with minimal agonism, that displayed excellent multispecies IV/PO pharmacokinetics (PK), CNS penetration, no induction of long-term depression (or cholinergic toxicity) and robust efficacy in novel object recognition (minimum effective dose = 3 mg/kg p.o.). Thus, VU6007496 can serve as another valuable in vivo tool compound in rats and nonhuman primates, but not mouse, to study selective M1 activation.
期刊介绍:
ACS Chemical Neuroscience publishes high-quality research articles and reviews that showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders. Research in the journal focuses on aspects of chemical neurobiology and bio-neurochemistry such as the following:
Neurotransmitters and receptors
Neuropharmaceuticals and therapeutics
Neural development—Plasticity, and degeneration
Chemical, physical, and computational methods in neuroscience
Neuronal diseases—basis, detection, and treatment
Mechanism of aging, learning, memory and behavior
Pain and sensory processing
Neurotoxins
Neuroscience-inspired bioengineering
Development of methods in chemical neurobiology
Neuroimaging agents and technologies
Animal models for central nervous system diseases
Behavioral research